Aspirinlow Dose
NDC Package 70882-122-30
Package Information
Aspirinlow Dose is •Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke (MI) in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. Marketed by Cambridge Therapeutics Technologies, Llc, this product is identified by NDC 70882-122 and is authorized under FDA application part343.
Identification & Billing
- RxCUI: 308416 - aspirin 81 MG Delayed Release Oral Tablet
- RxCUI: 308416 - ASA 81 MG Delayed Release Oral Tablet
- RxCUI: 308416 - aspirin 81 MG Enteric Coated Oral Tablet
- RxCUI: 309362 - clopidogrel 75 MG Oral Tablet
- RxCUI: 309362 - clopidogrel 75 MG (as clopidogrel bisulfate 97.875 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70882 - Cambridge Therapeutics Technologies, Llc
- 70882-122 - Aspirinlow Dose
- 70882-122-30 - 30 TABLET, COATED in 1 BLISTER PACK
- 70882-122 - Aspirinlow Dose
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70882-122-30 identifies a specific commercial package of 30 tablet, coated in 1 blister pack of Aspirinlow Dose Low Dose, labeled by Cambridge Therapeutics Technologies, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Cambridge Therapeutics Technologies, Llc on May 01, 2011. The current certification is valid through December 31, 2019.
How is this Cambridge Therapeutics Technologies, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70882012230. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.